What does geroFarma do?

geroFarma is a pharmacy in Kortrijk. Private Limited, started on 2 October 2021, 1 establishment.

What is the address of geroFarma?

The registered office of geroFarma is located at Albrecht Rodenbachlaan(Heu) 82, 8501 Kortrijk.

Is geroFarma still active?

Yes. According to the CBE (31 October 2026) geroFarma is active, legal situation “Normale toestand”, started on 2 October 2021.

Is geroFarma registered on Peppol?

Yes, geroFarma is registered on the Peppol network with ID 0208:0774941908.

What is the enterprise number of geroFarma?

The enterprise number of geroFarma is BE0774941908.

When was geroFarma founded?

geroFarma was founded on 2 October 2021.

Who are the directors of geroFarma?

According to the 2025 annual accounts, the directors of geroFarma are: Fien Loosveldt.

Is geroFarma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 October 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did geroFarma make in 2025?

geroFarma posted a profit after taxes of € 107,225 in financial year 2025.

What is the revenue of geroFarma?

As a small company, geroFarma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 185,196.

geroFarma (Private Limited) - Kortrijk - BE0774941908

Dossier geroFarma, printed on 31 October 2026 from databakkes.be/en/0774941908/gerofarma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

geroFarma from Kortrijk, company number BE0774941908, closed financial year 2025 with a result of € 107,225 after tax. For that financial year geroFarma recorded a gross margin of € 185,196 and equity of € 240,699. Compared with financial year 2024, the result moved from € 54,029 to € 107,225. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 11, 2026.

What it is worth Growing

€ 240,699

▲ 80% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 107,225

▲ 98% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 42,099

▲ 284% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 239,699.

People and assets in 2025

Vehicles and equipment

€ 30,349

▼ 23% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 15 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 751,650

▼ 6% vs 2024

€ 50,850 is repaid this year. At this pace the long-term loan is gone in ≈ 15 years.

Taxes and wages

€ 48,151

▲ 167% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 19,492 Gross margin 2022: € 19,492 First fiscal year in the series	€ 43,427 Gross margin 2023: € 43,427 ▲ 123% vs 2022 (€ 19,492) Favourable step	€ 105,483 Gross margin 2024: € 105,483 ▲ 143% vs 2023 (€ 43,427) Favourable step	€ 185,196 Gross margin 2025: € 185,196 ▲ 76% vs 2024 (€ 105,483) Favourable step	▲ 76%
Profit after taxes	€ 12,257 Profit after taxes 2022: € 12,257 First fiscal year in the series	€ 66,188 Profit after taxes 2023: € 66,188 ▲ € 53,931 vs 2022 (€ 12,257) Favourable step	€ 54,029 Profit after taxes 2024: € 54,029 ▼ 18% vs 2023 (€ 66,188) Unfavourable step	€ 107,225 Profit after taxes 2025: € 107,225 ▲ 98% vs 2024 (€ 54,029) Favourable step	▲ 98%
Equity	€ 13,257 Equity 2022: € 13,257 First fiscal year in the series	€ 79,445 Equity 2023: € 79,445 ▲ € 66,188 vs 2022 (€ 13,257) Favourable step	€ 133,474 Equity 2024: € 133,474 ▲ 68% vs 2023 (€ 79,445) Favourable step	€ 240,699 Equity 2025: € 240,699 ▲ 80% vs 2024 (€ 133,474) Favourable step	▲ 80%
Total debts	€ 801,506 Total debts 2022: € 801,506 First fiscal year in the series	€ 884,023 Total debts 2023: € 884,023 ▲ 10% vs 2022 (€ 801,506) Unfavourable step	€ 840,565 Total debts 2024: € 840,565 ▼ 5% vs 2023 (€ 884,023) Favourable step	€ 812,469 Total debts 2025: € 812,469 ▼ 3% vs 2024 (€ 840,565) Favourable step	▼ 3%
Cash	€ 24,710 Cash 2022: € 24,710 First fiscal year in the series	€ 10,581 Cash 2023: € 10,581 ▼ 57% vs 2022 (€ 24,710) Unfavourable step	€ 10,969 Cash 2024: € 10,969 ▲ 4% vs 2023 (€ 10,581) Favourable step	€ 42,099 Cash 2025: € 42,099 ▲ 284% vs 2024 (€ 10,969) Favourable step	▲ 284%
Retained profit	€ 12,257 Retained profit 2022: € 12,257 First fiscal year in the series	€ 78,445 Retained profit 2023: € 78,445 ▲ € 66,188 vs 2022 (€ 12,257) Favourable step	€ 132,474 Retained profit 2024: € 132,474 ▲ 69% vs 2023 (€ 78,445) Favourable step	€ 239,699 Retained profit 2025: € 239,699 ▲ 81% vs 2024 (€ 132,474) Favourable step	▲ 81%
Bank debt	€ 695,000 Bank debt 2022: € 695,000 First fiscal year in the series	€ 803,750 Bank debt 2023: € 803,750 ▲ 16% vs 2022 (€ 695,000) Unfavourable step	€ 802,500 Bank debt 2024: € 802,500 Unchanged (€ 803,750) Favourable step	€ 751,650 Bank debt 2025: € 751,650 ▼ 6% vs 2024 (€ 802,500) Favourable step	▼ 6%
Balance sheet total	€ 814,764 Balance sheet total 2022: € 814,764 First fiscal year in the series	€ 963,468 Balance sheet total 2023: € 963,468 ▲ 18% vs 2022 (€ 814,764) Unchanged	€ 974,039 Balance sheet total 2024: € 974,039 ▲ 1% vs 2023 (€ 963,468) Unchanged	€ 1,053,168 Balance sheet total 2025: € 1,053,168 ▲ 8% vs 2024 (€ 974,039) Unchanged	▲ 8%

Key figures of geroFarma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to geroFarma?

What happened at geroFarma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 11, 2026 New annual accounts for financial year 2025: profit of € 107,225 (▲ 98% vs 2024). Source: NBB ↗
2022 Fien Loosveldt became a director. NBB
Oct 2, 2021 New establishment in Kortrijk. KBO
Oct 2, 2021 Start of the company according to the CBE. KBO

In short

From € 12,257 profit in 2022 to € 107,225 profit in 2025.

Paid € 98,659 in corporate taxes since 2022.

Best year ever: 2025, with € 107,225 profit.

Original PDFs at the National Bank ↗

Management

Fien Loosveldt

geroFarma

FARMAVE 50%

SANPOHAR 50%

Behind geroFarma is Fien Loosveldt. It owns 50% of FARMAVE and 50% of SANPOHAR itself.

Directors

According to the 2025 annual accounts

Fien Loosveldt

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Albrecht Rodenbachlaan(Heu) 82

8501 Kortrijk

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0774.941.908

VAT number

BE 0774.941.908

Registered office

Albrecht Rodenbachlaan(Heu) 82, 8501 Kortrijk

Names & denominations

geroFarma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 October 2021

Peppol

Active · Active since 31 Oct 2023

Activities · NACE

Detailhandel in farmaceutische producten

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

geroFarma

Financials

What happened to geroFarma?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions